-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $225

Benzinga·02/11/2026 14:19:46
Listen to the news
Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $210 to $225.